The Nurse View.

Slides:

Advertisements

Similar presentations

Single-Patient Use of Investigational Drugs and Biologic Products for Treating Cancer Grant Williams, M.D. Medical Team Leader DODP/CDER/FDA.

Advertisements

Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.

Bladder Cancer: A New Era in Treatment

The Nurse View: Management of Pancreatic Cancer

State of the Art in BRCA-Mutated Ovarian Cancer

Evolving Paradigms in Recurrent/Metastatic SCCHN

This program will include a discussion of off-label treatment not approved by the FDA for use in the United States.

Challenges and Opportunities in the Management of ANCA-Associated Vasculitis.

An Introduction to DNA Damage Repair in Cancer: Beyond PARP

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

Optimizing Therapy for Osteoarthritis

PARP Inhibition: The New Frontier in Recurrent Ovarian Cancer

Progression After Cancer Immunotherapy in Advanced NSCLC

MOCA Living Well: Understanding PARP Inhibitors in Ovarian Cancer

Ask the Onychomycosis Expert, Part 2

Ask the Onychomycosis Expert, Part 1

Why Treat Seborrheic Keratosis?

The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer

Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?

The Nurse View: Updates in the Management of Metastatic Colorectal Cancer.

PARP Inhibitors and Cancer: What Do You Need to Know?

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

GEMSTONE Educational Case Summary

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Clinical Considerations in Evidence-based Management of GIST

Navigating the Data and Evolving Our Approach

The Nurse View.

Counseling Patients About Germline BRCA Mutations

Treatment Options to Consider

HCV Protease Inhibitors in Clinical Practice

Individualizing Care in Ovarian Cancer

Overview. Maximizing the Safety of CAR T-Cell Therapy: Prevention, Early Recognition, and Management.

Seizures in the Elderly: Treatment and Special Considerations

Using CDK4/6 Inhibitors to Manage HR-Positive Metastatic Breast Cancer

From Symptom Management to Communication in Advanced GI Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Rome IV: What Has Changed? Rome IV IBS Subtypes.

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

Poor Response to Initial Therapy for Migraine

Mutational Testing to Select Novel Targeted Therapies in AML

Extraordinary Cases of VTE Prevention in Patients With Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

When Is Biologic Therapy Appropriate for HS?

PARP Inhibitors and Ovarian Cancer: What Did Data From Washington, DC, Tell Us?

Oral Prostanoids and PAH

Maintenance Therapy in Advanced Ovarian Cancer

The Road to Quality Improvement in HER2-Positive Breast Cancer

PARP Inhibitors.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Molecular Testing in Ovarian Cancer: Is the Time Now?

Evaluating BTK Inhibitors in CLL

Oral Prostacyclin Pathway Agents in PAH

MAINTENANCE THERAPY WITH PARP INHIBITORS

Extraordinary Cases in VTE

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

Program Goal. Program Goal Disclaimer Overview.

Prioritizing Prevention of HPV-Related Disease

Volume 147, Issue 3, Pages (December 2017)

AMD Therapy: Where Are We Now and Where Are We Going?

Checkpoint Inhibitors in First-Line Advanced NSCLC

Clinical Considerations in Evidence-based Management of GIST

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.

Care Team Collaboration for CAR T-Cell Therapy: Real-World Advice

PCSK9 Inhibitors and Real-World Evidence

Navigating the Journey

Uncovering the Right Sequence

Optimizing Patient Outcomes in Metastatic Triple-Negative Breast Cancer.

Presentation transcript:

The Nurse View

Ovarian Cancer in the United States

FDA-Approved Drugs for Ovarian Cancer

Case Study Deborah

Genetic Testing in Ovarian Cancer

Case Study Deborah (cont)

Primary Systemic Therapy Options Stage IV Ovarian Cancer

Case Study Deborah (cont)

Treatment by Platinum Status at Recurrence

Case Study Deborah (cont)

PARP Inhibitors for Ovarian Cancer Overview

Maintenance Therapy Recommendations NCCN Guidelines

Initiating PARP Inhibitor Therapy Patient Education for Oral Medications

PARP Inhibitors Safety

Case Study Deborah (cont)

Managing GI Toxicity From PARP Inhibitors

Managing Anemia From PARP Inhibitors

Case Study Jane

Considerations for Elderly Patients

Case Study Jane (cont)

Signs and Symptoms of Thrombocytopenia

Managing Thrombocytopenia From Niraparib

Niraparib Dose Adjustments

Laboratory Abnormalities Associated With PARP Inhibitors

Key Takeaways

Resources for Patients and Oncology Nurses

Additional Online Resources

Abbreviations

Abbreviations (cont)